Programmed cell death 1 inhibitor sintilimab plus concurrent chemoradiotherapy for locally advanced pancreatic adenocarcinoma

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 15, Issue 7

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

All Articles published online

Item

Count

PDF

HTML

Tables (1-3)

Sum=7

Jul 24, 2024 (publication date) through Jul 16, 2024

Times Cited of This Article

Journal Information of This Article

Publication Name

World Journal of Clinical Oncology

ISSN

2218-4333

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

World J Clin Oncol. Jul 24, 2024; 15(7): 859-866
Published online Jul 24, 2024. doi: 10.5306/wjco.v15.i7.859

Table 3 Toxicity

Symptom	Control group, No. of patients				Observation group, No. of patients
Symptom	Grade 1	Grade 2	Grade 3	Grade 4	Grade 1	Grade 2	Grade 3	Grade 4
Leukopenia	11	7	3	1	12	8	4	1
Fatigue	15	6	2	0	16	9	2	0
Anemia	14	5	1	0	15	6	1	0
Nausea	18	8	0	0	20	10	1	0
Anorexia	8	5	0	0	11	7	0	0

Citation: Zhou SQ, Wan P, Zhang S, Ren Y, Li HT, Ke QH. Programmed cell death 1 inhibitor sintilimab plus concurrent chemoradiotherapy for locally advanced pancreatic adenocarcinoma. World J Clin Oncol 2024; 15(7): 859-866
URL: https://www.wjgnet.com/2218-4333/full/v15/i7/859.htm
DOI: https://dx.doi.org/10.5306/wjco.v15.i7.859